Business Wire

Copeland Expands Industrial Heat Pump Portfolio with Agreement to Acquire SPH Sustainable Process Heat

23.10.2025 23:30:00 EEST | Business Wire | Press release

Share

Copeland, a global leader in sustainable climate solutions, today announced its agreement to acquire SPH Sustainable Process Heat (SPH), a Germany-based industrial heat pump technology company. This acquisition is expected to expand Copeland’s industrial heating portfolio, allowing the company to deliver a broader range of key heat pump technologies and solutions to new and existing customers. Copeland’s industrial business operates under the brand name Vilter. SPH will continue to operate independently until closing.

This acquisition reinforces Copeland’s commitment to enabling the energy transition, in this case, through innovative technologies that enable industrial customers to replace fossil-fuel systems with more energy-efficient heating alternatives. SPH brings a strong technology portfolio, including its innovative ThermBooster™ technology, and demonstrated capability in delivering solutions to a broad range of industrial end-markets.

Headquartered in Overath, Germany, SPH helps customers with sustainable, heat-pump-based steam solutions that meet a wide range of temperature, capacity and refrigerant needs. SPH specializes in designing, manufacturing and servicing heat pumps for industrial steam applications for temperatures up to 180 degrees Celsius, with solutions that can utilize a wide range of natural and low global warming potential refrigerants.

This transaction is expected to expand Copeland’s Vilter industrial heating portfolio by serving process segments that demand higher-temperature steam. It will also expand the range of supported refrigerants, enabling optimized performance and efficiency, as well as cost-effective ownership and the potential to reduce emissions for industrial customers, depending on system growth design and operating conditions. Driven by strong end-market growth and technological leadership, forecasts have estimated that the European steam heat pump segment is poised for as much as double-digit growth over the coming years.

“The addition of SPH’s team and its differentiated technologies will enable us to serve a broader range of customers and applications,” says Ross B. Shuster, Copeland’s chief executive officer. “This broader portfolio positions Copeland well to expand our rapidly growing industrial business by helping address the world’s increasing demand for sustainable heating solutions.”

“We are truly excited to join the Copeland team,” said Andreas Muck, Tim Hamacher and Tor Hodne, founders of SPH. “By combining our high-temperature heat pump technology with Copeland’s expansive reach and expertise, we can help a broader range of industrial customers accelerate their transition to cleaner, more energy-efficient heating. Together, we’re committed to advancing global sustainability and empowering industries to meet ambitious electrification goals.”

The transaction is expected to close by the end of 2025, subject to customary closing conditions. Spirax Group (LON: SPX), a leader in steam solutions, currently holds and will continue to maintain a minority share in SPH under Copeland ownership. Through its Steam Thermal Solutions Business, Spirax Group intends to broaden SPH’s existing sales channels by marketing SPH’s heat pump solutions through its direct sales channel.

This announcement includes forward-looking statements regarding the proposed acquisition and its expected benefits. Actual results may differ due to market conditions or other factors. Copeland undertakes no obligation to update these statements.

About Copeland

Copeland is a global leader in sustainable heating, cooling, cold chain and industrial solutions. We provide mission-critical compression technologies and controls solutions for a broad range of commercial, industrial, refrigeration and residential customers. We address issues like climate change, growing populations, electricity demands and a complex global supply chain with innovations that advance the energy transition, accelerate the adoption of climate friendly low-GWP (global warming potential) and natural refrigerants and safeguard the world’s most critical goods through an efficient and sustainable cold chain. We have over 18,000 colleagues with feet on the ground in more than 40 countries – a global presence that makes it possible to serve customers wherever they are in the world and meet challenges with scale and speed. Our industry-leading brands and diversified portfolio deliver innovation and technology proven in over 200 million installations worldwide. Together, we create sustainable solutions that improve lives and protect the planet today and for future generations. For more information, visit copeland.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251023600378/en/

Contacts

PR@Copeland.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye